References:
1. Holl-Ulrich, K., [Vasculitis: New nomenclature of the Chapel
Hill consensus conference 2012]. Z Rheumatol, 2014. 73 (9):
p. 823-33; quiz 834-5.
2. Yazici, H., et al., Behçet syndrome: a contemporary view.Nature Reviews Rheumatology, 2018. 14 (2): p. 107-119.
3. Davatchi, F., et al., The International Criteria for Behçet’s
Disease (ICBD): a collaborative study of 27 countries on the sensitivity
and specificity of the new criteria. Journal of the European Academy of
Dermatology and Venereology, 2014. 28 (3): p. 338-347.
4. Yazici, H., The place of Behcet’s syndrome among the autoimmune
diseases. Int Rev Immunol, 1997. 14 (1): p. 1-10.
5. Gul, A., Behcet’s disease as an autoinflammatory disorder.Curr Drug Targets Inflamm Allergy, 2005. 4 (1): p. 81-3.
6. Franks, W.A., et al., Cytokines in human intraocular
inflammation. Curr Eye Res, 1992. 11 Suppl : p. 187-91.
7. Bouomrani S, T.S., Guermazi M, Regaïeg N, Thyroid Involvement
In Behçet’s Disease. Symbiosis, 2019(Int J Thyro Disord Ther 1 (1):
1-7).
8. Lockwood, C.M., et al., Remission induction in Behcet’s disease
following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H.Rheumatology (Oxford), 2003. 42 (12): p. 1539-44.
9. Colak, R., et al., A comparison between the effects of low (1
ug) and standard dose (250 ug) ACTH stimulation tests on adrenal cortex
functions with Behcet’s disease. Journal of the European Academy of
Dermatology and Venereology, 2006. 20 (6): p. 721-725.
10. Husebye, E.S., M.S. Anderson, and O. Kampe, Autoimmune
Polyendocrine Syndromes. N Engl J Med, 2018. 378 (12): p.
1132-1141.
Figure legends:
Figure 1 shows oral hyperpigmentation (orange arrows).